Compound class:
Synthetic organic
Comment: TAK-071 is a muscarinic M1 receptor positive allosteric modulator [1-2]. It has been shown to improve cognitive function in in vivo models.
|
|
No information available. |
Summary of Clinical Use ![]() |
TAK-071 has progressed to clinical trial to evaluate its efficacy to improve cognition in patients with Parkinson's and Alzheimer's diseases. Safety and pharmacokinetics in healthy subjects has been reported [3]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02769065 | Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants | Phase 1 Interventional | Takeda | ||
NCT04334317 | A Study of TAK-071 in People With Parkinson Disease | Phase 2 Interventional | Takeda |